CN Patent

CN109982687A — 联合疗法

Assigned to Pathway Therapeutics Inc · Expires 2019-07-05 · 7y expired

What this patent protects

本文提供了使用联合疗法来治疗疾病如癌症的方法。在某些实施方案中，所述方法包括向患者施用有效量的磷酸肌醇‑3‑激酶(PI3K)抑制剂和有效量的选自布鲁顿酪氨酸激酶(BTK)抑制剂、Bcl‑2抑制剂、EZH2抑制剂及其组合的第二药剂。

USPTO Abstract

本文提供了使用联合疗法来治疗疾病如癌症的方法。在某些实施方案中，所述方法包括向患者施用有效量的磷酸肌醇‑3‑激酶(PI3K)抑制剂和有效量的选自布鲁顿酪氨酸激酶(BTK)抑制剂、Bcl‑2抑制剂、EZH2抑制剂及其组合的第二药剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN109982687A
Jurisdiction
CN
Classification
—
Expires
2019-07-05
Drug substance claim
No
Drug product claim
No
Assignee
Pathway Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.